Hospitals participating in the 340B Drug Pricing Program, a large federal safety-net program, are financially incentivized to prescribe original biologic drugs to prevent and treat diseases in lieu of cheaper generic-like alternatives called biosimilar medications, according to a new study by Weill Cornell Medicine, NYU Grossman School of Medicine and University of Miami investigators.